Return to Today's science sparks archives
Click the tweet icon above each article title to share it on Twitter.
|
Abstract. Clearing agents (CAs) can rapidly remove nonlocalized targeting biomolecules from circulation for hepatic catabolism, thereby enhancing the therapeutic index (TI), especially for blood (marrow), of the subsequently administered radioisotope in any multistep pretargeting strategy.
|
|
|
Figure 1. Brief summary of key clinical trials for programmed cell death protein 1 (PD-1) or programmed death ligand 1 (PD-L1) blockade.
|
 |
|
Fig 3. DFS (A) and OS (B) for the entire cohort stratified by TMB using a binary cutoff of 2.8 (third quartile). OS by TMB in patients with fusion-negative RMS (C); fusion-positive RMS (D); localized RMS (low/intermediate risk; E); and metastatic RMS (high risk; F).
|
|
|
Fig 1. All-cause cumulative mortality more than 5 years from cancer diagnosis for cancer survivors
|
|
|
Fig 7. Model of oncogenic splicing factor mutation-induced altered splicing and aberrant NMD.
|
|
|
Fig 3. Bone marrow aspirate smears from patients with chromothripsis-negative AML-MRC revealed a typical myeloid blast morphology (Giemsa, ×1000).
|
|
|
Table 2. Results of the 2 rounds of rating.
|
|
|
Fig 1. Estimated absolute risk of developing breast cancer for women with germline PALB2 pathogenic variants (PVs) by age
|
|
|
Fig. 1. Synthesis and size characterization of fluorescent protein nanoparticles.
|
|
|
Figure 1. MRI imaging
|
|
|
Figure 2: Mathematical modeling predicts optimal treatment schedule.
|
|
|
Fig. 4: Monocytes do not persist in the peri-infarct area.
|
|
|
Fig. 4: CD36 deficiency stimulates apoptosis in intratumoral Treg cells.
|
|
|
Fig. 1. Study design. LAN–PRRT, lanreotide autogel/depot combined with peptide receptor radionuclide therapy.
|
|
|
Graphical Abstract.
|
|
|
Figure 1: Genomic alterations in sRCCs by targeted panel sequencing.
|
|
|
Graphical Abstract.
|
|
|
Fig 3. Schematic of skin surface co-registration.
|
|
|
Fig 1. Relative rank ordering of freelisting items (n = 65).
|
|
|
Figure 1. Planned intensity and duration of each individual session (ie, dose) and schedule of treatment dose across the study intervention period for linear dosing and nonlinear dosing.
|
|
|
Fig. 1: Clinical presentation and genetic features of patients with iMCD-TAFRO.
|
|
|
Figure 1.Three-dimensional waterfall and swim plots of arm A (A), arm B (B), arm C (C), arm D (D), and arm E (E).
|
|
|
Fig 5. FLARE in PML-RARα transgenic mouse model.
|
|
|
Fig 6. Advective flux vectors along the MCA show aberrant flow in SHRSP.
|
|
|
Fig. 4. Immune phenotype of KRAS co-mutated subgroups.
|
|
|
Fig 1. Genomic alterations in sRCCs by targeted panel sequencing
|
|
|
Fig 1. Ars2 is required for embryonic NSC development.
|
|
|
Fig 1. The Challenge of Optimizing FMT.
|
|
|
Fig 8. Energy spectra from PIV at LDA crossing for different optical turbulence strengths are consistent with spectra calculated from corresponding LDA data.
|
|
|
Central Illustration. Global Longitudinal Strain in Immune Checkpoint Inhibitor-Myocarditis
|
|
|
Fig 1. Transcriptional analysis of tumour specimens from patients with high-risk resectable melanoma and metastatic RCC treated with pre-surgical ICB
|
|
|
Fig 1. Individual responses by tumour type
|
|
|
FIGURE 1. Functional overlap of acute myeloid leukemia driver mutations.
|
|
|
Fig. 2. A-F. Trends in Death at Home or Hospice (1999–2017 aggregate data).
|
|
|
Table 1: Comfort level before and after mock drill.
|
|
|
Figure 1. Representative H&E, PD-L1 IHC, and CD8+ T-cell IHC of baseline colon tumor specimens of patients treated with pembrolizumab (anti–PD-1).
|
|
|
Fig. 1. Block diagram for CS and ROICS reconstruction based on reconstruction type selection and its results at the chosen acceleration factor for demonstrating its utility.
|
|
|
Figure 1. (A) The unique sampling geometry of golden‐angle radial sampling enables direct estimation of a temporal basis from the acquired data.
|
|
|
FIG 1. Sensitivity and specificity of human papillomavirus (HPV) types 16 and 33 droplet digital polymerase chain reaction (ddPCR) assays.
|
|
|
Fig 2. Cumulative incidence of grades 3-5 cardiac outcomes among survivors of cancer in childhood by decade of cancer diagnosis and siblings.
|
|
|
Fig. 1: Best percent change in target lesions from baseline in MET-exon-14-altered NSCLCs.
|
|
|
Fig.1. Conceptual Framework
|
|
|
Figure 6. Impact of 3′-terminal quadruplets on sequence selectivity of Rrp6p.
|
|
|
Figure 4. Existing classification systems are interconnected.
|
|
|
Figure 1. A, Epithelioid malignant mesothelioma shows malignant rounded epithelioid cells.
|
|
|
Graphical Abstract
|
|
|
Fig. 1 Characterization of batch-produced microparticles with cell-like mechanical properties.
|
|
|
Fig. 1 (a) Schematic of RStudio/shiny running on a server (“in the cloud”), immediately processing the user’s selections and rendering the new analysis in real time.
|
|
|
Graphical Abstract
|
|
|
Fig 3. (A) Change in skin modified Severity Weighted Assessment Tool (mSWAT) scoring for patient 17 with transient skin flare reaction.
|
|
|
Fig 3. Pathologic and genomic correlates of response.
|
|
|
Fig 3. Correlation heat map based on univariate linear regression analysis between each individual MR imaging phenotype and the recurrence predictor models of MammoPrint, Oncotype DX, PAM50 ROR-S, and PAM50 ROR-P.
|
|
|
Fig 2. AdnAB complex with forked duplex DNA.
|
|
|
Graphical Abstract.
|
|
|
Figure 2. B7–H3 expression across WHO grade.
|
|
|
Fig 2. MR images of a partial response (ongoing) achieved after 8 weeks of dabrafenib therapy in an 11-year-old male patient with BRAF V600–mutant ganglioglioma determined using coronal T1 postgadolinium contrast sequence.
|
|
|
Fig. 1: ENL mutations drive aberrant developmental programs and impair nephron differentiation.
|
|
|
Fig 2. Open in figure viewerPowerPoint
High‐grade endometrial stromal sarcoma (HGESS) harbouring BCOR internal tandem duplication (ITD).
|
|
|
Fig 1. Patients classified by radiologically assessed response to immunotherapy.
|
|
|
Graphical Abstract
|
|
|
Fig. 3. The multi-step protocol used to provide a multianalyte gene expression assay result for GEP-NETs.
|
|
|
Figure 3. Etv6 binding precedes cohesin binding at cis-regulatory elements of genes upregulated during erythropoiesis.
|
|
